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Abstract
Gallbladder cancer (GBC) is the most frequent malignancy of the biliary tract, represent-
ing about 85–90% of the cancers involving this anatomical district; it is characterized 
by high mortality rates with less than 10% of the sufferers surviving more than 5 years. 
Extensive scientific research is needed in order to identify biomarkers for early diagnosis, 
improve the treatment options available, and assess new effective therapies. Consistent 
improvements have been made in recent years in the field of noncoding RNAs. More than 
90% of the human genome is constituted by a noncoding portion that actively transcribes 
an enormous and complex amount of RNA, while only approximately 2% represents 
the coding genes. Noncoding RNAs are divided into two categories in accordance with 
their dimensions: small RNAs, which are made by less than 200 nucleotides, and long 
RNAs, which are bigger. MicroRNAs (miRNAs) and long noncoding RNA (lncRNAs) 
are the main subclasses, respectively, which concentrate consistent scientific efforts in 
recent times with promising results in several diseases, including cancer. In this review, 
we summarize the roles of miRNAs and lncRNAs in gallbladder cancer pathophysiology 
and their possible translational implication in the diagnosis and treatment of this aggres-
sive disease.
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1. Introduction
Gallbladder cancer (GBC) is the most frequent malignancy of the biliary tract, representing 
about 85–90% of the cancers involving this anatomical district. Furthermore, it is the main 
cause of death among biliary tract tumors [1]. More than 76,000 cases of gallbladder cancer 
have been estimated worldwide in 2012; two thirds were registered in less developed areas of 
the globe [2]. At the same time, more than 60,000 deaths were estimated worldwide, evidencing 
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that incidence and mortality rates are very close [2]. Indeed, the absence of specific clinical 
manifestations in the early stages of the disease, along with the lack of specific biological 
markers, makes the prompt diagnosis challenging, and a great part of the patients presents 
with advanced stage local or metastatic lesions. Most of those who receive surgery, chemo-
therapy, and/or radiotherapy develop early recurrences or do not respond to treatments; 
as a result, the overall survival is poor, with less than 10% of the sufferers surviving more 
than 5 years [3]. This makes necessary further scientific efforts in order to identify trustful 
biomarkers for early diagnosis, improve the treatment options available, and assess new 
effective therapies.
Interesting developments were made in recent years in the study of noncoding RNAs 
(ncRNAs) and their involvement in cancer development, growth, and dissemination. Results 
of the human genome project and other next-generation sequencing studies evidenced that 
the approximately 20,000 protein-coding genes represent approximately 2% of the human 
genome, while more than 90% is made by a noncoding portion that actively transcribes an 
enormous and complex amount of RNA [4]. This part of the transcriptome has been called 
“dark matter” in the past because it has been interpreted as transcriptional debris; neverthe-
less, recent advantages confirmed that this huge amount of ncRNA displays numerous roles 
in the normal cellular biology, as well as in many pathological processes.
The group of ncRNAs is commonly divided into two further categories, according to their 
size. The first one includes small ncRNAs, like the recently discovered microRNAs (miRNAs), 
small interfering RNAs (siRNAs), small nucleolar RNAs (snoRNAs), and others, in addition to 
the classical cellular RNAs (ribosomal, transfer, and other RNAs). miRNAs are RNAs approx-
imately 22 nucleotides long, which function as intricate components of cellular networks 
involved in the specific regulation of both protein-coding and noncoding genes, generally by 
posttranscriptional silencing [5, 6]. The Figure 1 summarizes the main types of ncRNAs cur-
rently known. Noncoding RNAs greater than 200 nucleotides represent the remaining cate-
gory, including molecules defined long noncoding RNA (lncRNAs). This merely dimensional 
definition of lncRNAs has some limitations, like the arbitrary cutoff value and the real protein 
coding potential, and this reflects the complexity of this group of molecules [7].
Figure 1. According to the length of RNA chain, RNA molecules of the human genome can be classified in small RNA 
and long RNA. Generally, small RNAs are shorter than 200 nucleotides (nt) in length, while long RNAs are made 
by more than 200 nt. Long RNAs, also called large RNAs, include mainly the long noncoding RNAs (lncRNAs) and 
the messenger RNA (mRNA). Small RNAs mainly include ribosomal RNA (rRNA), transfer RNA (tRNA), microRNAs 
(miRNAs), small-interfering RNAs (siRNAs), small-nucleolar RNAs (snoRNAs), piwi-interacting RNAs (piRNAs), 
tRNA-derived small RNAs (tsRNAs), and small rDNA-derived RNAs (srRNAs).
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2. MicroRNAs in gallbladder cancer
MicroRNAs (miRNAs) are endogenous noncoding RNAs that bind to the 3’ untranslated 
region (UTR) of a target messenger RNA (mRNA), specifically in a sequence called miRNA 
recognition element (MRE), which can be fully or partially complementary. They are essen-
tial posttranscriptional regulators of multiple genes and determine the function of the cells 
under physiological and in several pathological conditions. Since 1993, when they were dis-
covered, hundreds of miRNAs have been characterized, and they are being widely studied 
as an important biological compound with promising prospects as diagnostic and prognostic 
biomarkers and as therapeutic targets. A number of studies on the roles of several miRNAs in 
the pathogenesis of GBC have been recently published; numerous miRNAs exhibit expression 
changes, with most of them being upregulated in neoplastic cells and tissues, and further evi-
dences confirmed their biological effects as either oncogenes or tumor suppressors (Table 1).
2.1. Onco-suppressor miRNAs in gallbladder cancer
Ten different miRNAs have been demonstrated to have onco-suppressive properties in recent 
studies (Table 1). miRNA-1 and miRNA-145 were analyzed in a study in which a significance 
analysis of microarrays (SAM) algorithm was employed to identify a set of 36 miRNAs consis-
tently downregulated in GBC compared to normal gallbladder tissue. The real time (RT-PCR) 
miRNA Main effect Interactions References
miRNA-1 Onco-suppressor VEGF-A and AXL [8]
miRNA-145 Onco-suppressor AXL [8]
miRNA-135a-5p Onco-suppressor VLDLR [9]
miRNA-26a Onco-suppressor HMGA2 [10]
miRNA-34a Onco-suppressor PNUTS [11]
miRNA-355 Onco-suppressor [12]
miRNA-130a Onco-suppressor HOTAIR, cMyc [13]
miRNA-218-5p Onco-suppressor BMI1, CCT1 [14]
miRNA-146b-5p Onco-suppressor EGFR [15]
miRNA-143 Onco-suppressor [16]
miRNA-155 Oncogenic [19]
miRNA-20a Oncogenic Smad7 [17]
miRNA-182 Oncogenic CADM1 [18]
miRNA-21 Oncogenic PTEN [20]
miRNA-187 Oncogenic [21]
miRNA-122 Oncogenic [21]
Table 1. The miRNAs most studied in gallbladder cancer.
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analysis confirmed the statistically significant reduced expression of miRNA-1 and miRNA-
145 in tumors and GBC cell lines [8]. The ectopic expression of miRNA-1 and miRNA-145 in 
NOZ cell lines of GBC significantly repressed cell viability and colony formation, while only 
miRNA-1 reduced gene expression of known oncogenes, such as the vascular endothelial 
growth factor A (VEGF-A) and AXL receptor tyrosine kinase (AXL), suggesting that these 
miRNAs act as tumor suppressors in GBC [8].
Also miRNA-135a-5p has been demonstrated to be an onco-suppressor in gallbladder cancer. 
Its levels have been found to be significantly downregulated in GBC tissues and were corre-
lated with the histological grade of the tumors [9]. Furthermore, the transfection of a miRNA-
135a-5p mimetic inhibited proliferation and colony formation of GBC cells by G1/S phase 
cell-cycle block; lentivirus-mediated overexpression of miRNA-135a significantly reduced the 
proliferation of GBC cells. In addition, xenografts from miRNA-135a–infected cells in nude 
mice were significantly smaller compared to controls [9]. These evidences suggested the onco-
suppressive role of this miRNA in GBC.
Also, miRNA-26a has a similar role. The expression of miRNA-26a was associated with the 
pathological stage of GBC in a recent study, which also demonstrated that miR-26a con-
tributed in reducing neoplastic cell proliferation. The authors found that the introduction 
of high-mobility group AT-hook 2 (HMGA2), whose expression is inversely related to the 
levels of miRNA-26a, eliminated its effect on GBC cells [10]. In other words, the alterations 
of neoplastic cell proliferation induced by miRNA-26a in GBC appear to be intermediated by 
HMGA2 [10].
In another recent article, the levels of miRNA-34a and the telomere length were evalu-
ated in 77 GBCs and 36 peri-tumoral tissues by RT-PCR [11]. The study evidenced a sig-
nificantly reduced expression of miRNA-34a and longer telomere length in GBC tissues. 
Furthermore, it was found that the reduced expression of miRNA-34a was a negative 
prognostic factor. Remarkably, induced overexpression of miRNA-34a in vitro reduced the 
colony-forming capacity of GBC stem-like cells and repressed xenograft neoplastic growth 
in vivo [11].
The reduced expression of miRNA-335 has been found to be associated with aggressive clini-
cal and pathological properties of GBC, specifically with high histologic grade, advanced 
clinical stage, and positive lymph node metastasis [12]. Furthermore, a reduced expression of 
miRNA-335 in GBC patients was associated with poor prognosis [12].
Also, miRNA-130a was found to be significantly downregulated in cancer tissues, compared 
with adjacent normal tissues; furthermore, its levels were negatively correlated to a lncRNA, 
HOX transcript antisense RNA (HOTAIR), which has been shown to be correlated with the 
metastatic progression of several carcinomas, and as a consequence, to be a negative prognos-
tic factor [13]. We will return in this interaction later in this chapter, talking about lncRNAs 
in gallbladder cancer. A similar interaction is also displayed between miRNA-218-5p and 
lncRNA CCT1; the later negatively regulates miRNA-218-5p which, in turn, inhibits GBC cell 
invasion, migration, and proliferation by targeting the B-cell–specific moloney murine leuke-
mia virus integration site 1 (Bmi1) [14].
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The expression level of miRNA-146b-5p was similarly downregulated in GBC tissues com-
pared with that in adjacent healthy tissues and was significantly correlated with tumor size 
and development in a study published by Cai et al. [15]. Moreover, high levels of miRNA-
146b-5p in gallbladder neoplastic cells repressed malignant growth by provoking apoptosis 
and G1 phase cell-cycle block. In addition, the authors established that the amounts of epi-
dermal growth factor receptor (EGFR) mRNA and those of miRNA-146b-5p were inversely 
related; this led them to the conclusion that EGFR can be considered as a mediator of the 
oncologic functions of miRNA-146b-5p in GBC [15].
Finally, miRNA-143 was found to be downregulated in studies performed by miRNA micro-
array analysis in GBC tissues, in comparison to adjacent healthy tissues [16]. Using blood 
samples from 40 GBC patients and healthy volunteers, the aberrant expression pattern of 
miRNA-143 was confirmed, and it was also evidenced that its expression levels were corre-
lated with lymph node metastasis and the pathological TNM stage of the disease.
2.2. Oncogenic miRNAs in gallbladder cancer
Six miRNAs with an oncogenic activity in GBC have been reported in recent studies (Table 1): 
miRNA-155, miRNA-20a, miRNA182, miRNA-21, miRNA187, and miRNA-122 [17–21]. All 
of them have been found to be upregulated in neoplastic tissues in comparison to healthy 
tissues, while miRNA-187 and miRNA-122 have been determined also in blood samples. 
Some of them display interesting interactions with other molecular networks. For example, 
miRNA-20a was evidenced to play an essential role in the metastatic progression and poor 
survival of GBC by targeting the mothers against decapentaplegic homolog 7 (Smad7)-β-
catenin axis [17]. Downregulation of miRNA-20a by a specific antagonist effectively restored 
the expression of Smad7 in GBC cells in vitro and in vivo and weakened transforming growth 
factor (TGF)-β–induced cell metastasis.
A similar situation was observed regarding the miRNA-182. In a recent study, it was found 
that the TGF-β–induced overexpression of miRNA-182 promoted GBC cell migration and 
invasion, while its inhibition produced the arrest of neoplastic progression [18]. Furthermore, 
the reduction of miR-182 expression by means of a specific inhibitor in vivo had a negative 
impact on the incidence of GBC lung metastases. Interestingly, the cell adhesion molecule 1 
(CADM1) gene was identified as a novel molecular target of miRNA-182; its ectopic expres-
sion in GBC cells led to decreased tumoral invasion [18].
3. LncRNAs in gallbladder cancer
The first lncRNA, lncRNAH19, has been discovered in 1990 by Brannan et al. [22]. Since then, 
a great number of further lncRNAs have been discovered, and several digital databases pro-
vide information about their molecular features and their biological functions [7]. More than 
6700 lncRNA genes have been identified in the human genome in recent times [23]. Generally, 
their length reaches 100 kilobases, without significant open reading frames (ORF); they are 
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transcribed by RNA polymerase II or III and can be polyadenylated or not, spliced or not, 
nuclear or cytoplasmic. Their expression levels are usually lower than those of the protein-
coding genes, and a certain tissue-specificity has been described.
Several classifications of lncRNAs, based on different criteria, have been proposed. A first 
classification, based on their location on the genome, divides the lncRNAs into five groups: 
(a) sense, when they overlap with the exons of a different transcript on the same strand, (b) 
antisense, when they overlap with the exons of a different transcript on the opposite strand, 
(c) intronic, when they originate from an intron of a different transcript, (d) bidirectional, 
when the lncRNA and an adjacent transcript on the opposite strand are expressed at the same 
time, and (e) intergenic, when located in a region not affected by other coding sequences [24]. 
From a strictly functional perspective, Isin and Dalay classified lncRNAs in three categories: 
(a) the lncRNAs guides which can bind and guide cellular proteins toward their target, (b) 
the lncRNAs scaffolds which can bind effector molecules and initiate the formation specific 
molecular complexes, and (c) the lncRNAs which can bind proteins or RNA molecules and 
thus prevent these from exerting their function (we could call them “inhibitors”) [7].
The lncRNAs are implicated in a wide range of pre- and posttranscriptional functions, 
including nuclear architecture and import, immunity, imprinting, epigenetic regula-
tions, cellular trafficking, splicing, precursors of smaller RNAs, and pluripotency of the 
embryonic stem cells. LncRNAs can regulate gene expression at different levels including 
chromatin modifications, transcription, splicing, translation, posttranscriptional regula-
tion, processing of small RNAs, as well as several other functions [7]. They can affect and 
regulate the cell cycle and proliferation, differentiation and apoptosis and are involved in 
cancer development, maintenance, and progression [25]. Indeed, recent articles evidenced 
that approximately 18% of the total human lncRNAs are associated with several types of 
tumors [26]. The role of lncRNAs in gallbladder cancer has been investigated only in very 
recent years. Data about the roles of eleven lncRNAs have been published in the last three 
years; among them, eight have been demonstrated to be oncogenic and three onco-suppres-
sors (Table 2).
3.1. Onco-suppressor lncRNAs
Three different lncRNAs have been found to display an onco-supressive role in gallblad-
der cancer (Table 2): GCASPC, LET, and MEG. In a study published in 2016, Ma et al. used 
RT-PCR to measure GCASPC levels in tissues from 42 gallbladder cancer patients, and the 
levels of GCASPC were further confirmed in a separate cohort of 89 gallbladder cancer 
patients [27]. Its levels were significantly lower in neoplastic than adjacent nontumor tis-
sues and were associated with tumor size, stage, and prognosis. GCASPC overexpression 
suppressed cell proliferation in vitro and in vivo, whereas its silencing had opposite effects. 
The authors also identified pyruvate carboxylase as an RNA-binding protein associated to 
GCASPC. Because GCASPC is a target of miR-17-3p, they evidenced that both miR-17-3p and 
GCASPC downregulated pyruvate carboxylase level and activity. The authors defined this 
way a novel mechanism of lncRNA-regulated cell proliferation in gallbladder cancer, creating 
a new basis for understanding its pathophysiology [27].
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The same research group in a previous study evidenced that low levels of the lncRNA LET 
were associated with a less differentiated histology, advanced nodal status, and tumor stage, in 
relation to GBC patients with high LET expression [28]. Moreover, the overall 5-year survival 
rates of low and high LET expression groups was approximately 38 and 67%, respectively, 
with the low expression of this specific lncRNA being a significant predictor of metastasis and 
death in GBC patients [28]. Interestingly, the authors evidenced also that hypoxia correlated 
with decreased lncRNA LET levels in GBC EZ-GB2 and SGC-996 cells. They demonstrated 
that the invasive potential of GBC cells significantly decreased in cells overexpressing LET 
under hypoxia, while the invasive potential of GBC cells enhanced in LET knockdown cells 
under hypoxic conditions. They also showed that under hypoxic conditions, LET inhibited 
GBC cell proliferation by inducing a G0/G1 arrest, further confirming the tight connection 
between hypoxia and LET effects [28].
Regarding MEG3, Liu et al. demonstrated an approximately 6.25-fold reduction in its expres-
sion in GBC tissues compared to normal tissue samples [29]. The transfection of pcDNA-MEG3 
plasmids in human GBC GBC-SD and QBC939 cell lines resulted in reduced tumorigenic 
potential. When 5-week-old male athymic BALB/c mice were injected with GBC transfected 
cells, smaller tumors resulted compared to those treated with an empty vector. pcDNA-
MEG3 plasmid transfection in GBC cells induced the accumulation of p53 protein and reduc-
tion of the cyclin D1 gene expression. These transfected cell lines showed an accumulation of 
cells at the G0/G1 phase, lower expression levels of ki-67, and higher expression levels of 
Caspase-3, which implies that MEG3 also plays a vital role in the induction of apoptosis in 
GBC [29].
LncRNA Main effect Interactions References
AFAP-AS1 Oncogenic MET proteins [30]
ANRIL Oncogenic p53, p15INK4b, p16INK4a, cell 
cycle and apoptosis proteins
[29]
CCAT1 Oncogenic miRNA 218-5p, Bmi1 [14]
GCASPC Onco-suppressor miRNA 17-3p, pyruvate 
carboxylase
[27]
H19 Oncogenic miRNA 194-5p, AKT2, MET 
proteins
[31, 32]
HOTAIR Oncogenic miRNA 130a [13]
ITGB1 Oncogenic B-catenin, TCF8, MET proteins [34]
KIAA0125 Oncogenic B-catenin, MET proteins [33]
LET Onco-suppressor p21, Bax/Bcl-2, apoptosis proteins [28]
MALAT1 Oncogenic ERK/MAPK [35]
MEG3 Onco-suppressor p53, cell cycle and apoptosis 
proteins
[29]
Table 2. The main lncRNAs studied in relation to their role in gallbladder cancer pathophysiology.
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3.2. Oncogenic lncRNAs
Eight different lncRNAs showed oncogenic potential in GBC (Table 2): AFAP1-AS1, ANRIL, 
CCAT1, H19, HOTAIR, ITGB1, KIAA0125, and MALAT-1. In a recent study, Ma et al. analyzed 
the lncRNA AFAP1-AS1 expression by RT-PCR in 40 gallbladder cancer tissues and adjacent 
normal tissues [30]. The authors evidenced that the expression of lncRNA AFAP1-AS1 was 
significantly elevated in GBC tissues and GBC cell lines. In addition, its expression levels 
were significantly associated with tumor sizes and prognosis. Knockdown of AFAP1-AS1 
suppressed cell growth and invasion in NOZ and GBC-SD cells. Furthermore, they found that 
knockdown of AFAP1-AS1 in GBC cells inhibited EMT by downregulating the transcription 
factor Twist1 and Vimentin and upregulated the E-cadherin [30].
The role of lncRNA ANRIL in the pathogenesis of GBC was studied by Liu et al. together with 
that of MEG3 mentioned before [29]. In that study, GBC tissues and adjacent normal samples 
were collected from 84 patients, and empty vector and pcDNA-ANRIL vectors were transfected 
into GBC-SD and QBC939 cells. The expression of ANRIL was significantly higher in GBC and 
pcDNA-ANRIL-transfected cells in comparison to controls, and it was associated with prognosis. 
Even if mice injected with pcDNA-ANRIL showed contrasting results, the authors concluded 
that ANRIL can improve the proliferation of gallbladder cells and inhibit apoptosis [29].
Recently, Ma et al. demonstrated an approximately 1.5-fold upregulation of CCAT1 in 40 GBC 
tissues compared to paired normal tissues [14]. The expression of CCAT1 was higher in tumors 
extending beyond the gallbladder, with a stage-dependent pattern of expression. Similarly, 
overexpression of CCAT1 was found to be significantly associated with lymph node invasion 
and advanced node metastasis, highlighting its role in metastasis in GBC. As we mentioned 
before, the authors further observed that ectopic expression of CCAT1 increased the transcript 
level of Bmi1 in GBC-NOZ cells, while it decreased the expression level of miRNA-218-5p 
which has a tumor suppressive activity in several carcinomas and regulates the Bmi1 gene 
expression. They advocate that CCAT1 up-regulates Bmi1 by competitively ‘sponging’ the 
tumor suppressor miRNA-218-5p, as both shared the same miRNA responsive element in 
their sequences and displayed the same miRNA-218-5p-dependent regulation pattern [14].
Similar evidences were found about the lncRNA H19, which was found to be significantly 
upregulated in GBC tissues compared to adjacent noncancerous tissue and was positively 
correlated with tumor size and decreased survival of GBC patients [31, 32]. Its oncogenic 
role was further experimentally confirmed in a 4-week-old male athymic nude mice model 
of human GBC. In addition, the ectopic expression of H19 led to decreased expression of 
E-cadherin, and increased the expression of Vimentin and Twist1, in cell lines as well as in 
mice [32]. Interestingly, it was found that H19 positively regulates the expression of the AKT2 
gene (a putative oncogene) while reduces the levels of miR-194-5p, which demonstrated 
tumor-suppressive activity in several cancers [31].
Moreover, the levels of lncRNA HOTAIR were significantly higher in 65 GBC tissues, espe-
cially in those in higher pathological stage, in a recent report [13]. At a molecular level, 
HOTAIR expression was shown to be regulated by c-Myc [13]. As we mentioned before, regu-
lators of HOTAIR activity include miRNA-130a, a tumor suppressor miRNA, and this reflects 
the complexity of the regulatory networks in gallbladder cancer, which include several types 
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of ncRNAs and coding genes. Ectopic expression of HOTAIR reduced the level of miRNA-
130a, while miRNA-130a inhibition upregulated HOTAIR. Furthermore, it was demonstrated 
that depletion of HOTAIR inhibited the invasion of GBC cells, while a miRNA-130a inhibi-
tor reversed this decrease in invasiveness of GBC cells. Moreover, the depletion of HOTAIR 
resulted in the suppression of cell proliferation [13].
Both the lncRNAs ITGB1 and KIAA0125 were found to be overexpressed in GBC tissues, and 
both of them influence the GBC cell migration and invasion, in part through the alteration of 
Vimentin and β-catenin levels [33, 34]. Also, MALAT1 was significantly upregulated in GBC 
tissues compared with corresponding noncancerous tissues [35]. Knockdown of MALAT1 in 
GBC cell lines (SGC-996 and NOZ) significantly inhibited the proliferation and metastasis of 
the GBC cells both in vitro and in vivo (xenograft BALB/c nude mouse model of human GBC). 
Furthermore, the ERK/MAPK pathway was found to be inactivated in the GBC cell lines after 
MALAT1 knockdown, as it significantly reduced the levels of phosphorylated MEK1/2, ERK 
1/2, MAPK, and JNK 1/2/3 proteins, with no changes in their total levels. This suggests that 
MALAT1 acts as an oncogenic lncRNA that promotes proliferation and metastasis of GBC 
and activates the ERK/MAPK pathway [35].
4. Future perspectives
As we mentioned before, the number of the noncoding RNAs of the human genome, both 
miRNAs and lncRNAs or other species, is enormous, as is the number of their possible inter-
actions with a myriad of biological networks in healthy and neoplastic tissues. This reflects 
how little we know about them, and the huge scientific efforts which should be made in the 
future in order to better understand their pathophysiological roles and use them as diagnostic 
or prognostic markers, as well as targets for effective specific therapies. This would be particularly 
desirable in malignancies such as GBC, characterized by an aggressive clinical behavior and 
poor prognosis.
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